New Jersey Commits $16.5 Million to Eight Startups, Six in Health

New Jersey has approved $16.5 million in state equity for eight early-stage companies since February, with six of them working in health care, medical devices or biotechnology. The New Jersey Economic Development Authority (NJEDA), the Trenton-based state agency, announced the approvals on October 16, 2026. All came through the New Jersey Innovation Evergreen Fund (NJIEF), under which the state co-invests alongside venture firms.

"My Administration is committed to making New Jersey the best place to do business. By supporting these innovative companies, we are seeding new and important technologies, attracting incremental capital to New Jersey, and building a dynamic start-up ecosystem," said Mikie Sherrill, Governor of New Jersey.

The rhetoric is familiar. The dollar amounts are modest. And the program's own accounting suggests scale: $16.5 million across eight companies averages roughly $2 million per deal.

How does the Evergreen Fund actually work?

The state acts as an equity investor in early-stage companies, deploying up to $600 million alongside venture capital firms that it matches with New Jersey businesses. The fund is financed through tax credit sales. Purchasers fund investments made by Qualified Venture Firms (QVFs) and commit to strategic support for the state's innovation ecosystem — university partners, nonprofits, Strategic Innovation Centers, plus mentoring and educational programs. Those commitments are scored as part of each purchaser's bid.

"The NJIEF's success is measure[d] not just in dollars invested, but in the transformative impact it has had on New Jersey businesses," said Evan Weiss, Chief Executive Officer of NJEDA. He did not specify what that impact amounts to in jobs or returns.

Which health companies got the money?

Urologic Health, a Jersey City medical device company incubated at the MEDX Xelerator in Israel and now based at Liberty Science Center, received $1.25 million. It is developing what it describes as the first fully non-invasive urodynamic diagnostic system for bladder function — the current standard test, per NJEDA, requires catheterization. Edge Medical Ventures, which previously co-invested in Synchrony Medical through the program, made the match.

TangGene, a New Brunswick biotech, was approved for up to $1.5 million via Oak BioCapital. It is developing an investigational injectable drug for autoimmune diseases, starting with multiple sclerosis, designed to retrain the immune system to target disease-causing cells while leaving the rest of the immune system intact.

AstraNu, a Murray Hill company founded in 2025, was approved for up to $1.5 million alongside Celesta Capital. A Nokia Bell Labs spin-out, it is commercializing an integrated Optical Coherence Tomography "engine module" for low-cost eye care imaging — a single-chip design the company claims is 10 times smaller and cheaper than traditional parts. AstraNu is the first venture from Celesta's long-term commercialization partnership with Nokia.

Elligint Health, based in Edison, received $1.5 million matched by HLM Investment Partners. Its cloud-based Helios platform gives health insurers' care managers a single system for patient information on high-risk patients, prioritizing tasks and generating care plans automatically.

Why did South Jersey draw Rittenhouse?

Two of the health companies are based in South Jersey, and both were matched with Rittenhouse Ventures.

• ChorusRx (formerly GalenusCare), a Mount Laurel pharmacy and medication-risk management company serving high-risk, high-acuity patients such as those in hospice and chronic care, received almost $1 million. Its APPRAISE platform uses AI-driven regimen-level risk scoring to optimize medication.
• Sena Health, of Mickleton, received $750,000. It pairs AI agents with clinically trained human coordinators through its Access Command Center, providing round-the-clock scheduling, triage, care navigation, referral management and revenue cycle support for medical groups, health systems and employers.

These are Rittenhouse's second and third investments under the program; its first was a co-investment in New Jersey-based transcendAP in November 2025.

"Through the NJ Innovation Evergreen Fund and our partnership with NJEDA, we are proud to support category-defining healthcare companies in South Jersey like ChorusRx and Sena Health, and put more capital behind New Jersey innovators who are transforming patient outcomes," said Saul Richter, Founder & Managing Partner of Rittenhouse Ventures.

What about the non-health deals?

The two largest approvals went outside health care. Cranium AI, a Short Hills AI security company, received $5 million matched by SYN Ventures. Princeton Critical Minerals (PCM), a Newark company that emerged from Princeton University, received $4 million matched by SOSV for its lithium extraction technology — together, more than half the announced total.

What happens next?

The fund holds about $46 million in unallocated capital for new New Jersey investments, funded in part by $85 million in tax credits NJEDA auctioned last year. To date, the program has approved 37 venture firms and made direct investments in 20 businesses; firms can apply to become QVFs on a rolling basis.

"By delivering a robust roster of venture capital firms to cutting-edge startups, the NJIEF is fueling job creation and driving economic development across the state," said Kathleen Coviello, Chief Economic Transformation Officer of NJEDA.

Job-creation figures were not part of the announcement. The pace — 20 direct investments against a $600 million deployment ceiling — leaves the state's stated ambition still largely unfunded.